These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1424641)

  • 1. Excretion balance and urinary metabolic pattern of [3H]cabergoline in man.
    Cocchiara G; Benedetti MS
    Drug Metabol Drug Interact; 1992; 10(3):199-211. PubMed ID: 1424641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man.
    Battaglia R; Strolin Benedetti M; Mantegani S; Castelli MG; Cocchiara G; Dostert P
    Xenobiotica; 1993 Dec; 23(12):1377-89. PubMed ID: 7907829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic fate of FCE 22716, a new antihypertensive agent, and of its N-oxide (FCE 24220) in the rat.
    Cocchiara G; Battaglia R; Fontana E; Benedetti MS
    Drug Metabol Drug Interact; 1992; 10(3):185-97. PubMed ID: 1424640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection.
    Pianezzola E; Bellotti V; La Croix R; Strolin Benedetti M
    J Chromatogr; 1992 Feb; 574(1):170-4. PubMed ID: 1352782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers.
    Persiani S; Sassolas G; Piscitelli G; Bizollon CA; Poggesi I; Pianezzola E; Edwards DM; Strolin Benedetti M
    J Pharm Sci; 1994 Oct; 83(10):1421-4. PubMed ID: 7884663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers.
    Persiani S; Rocchetti M; Pacciarini MA; Holt B; Toon S; Strolin-Benedetti M
    Biopharm Drug Dispos; 1996 Jul; 17(5):443-55. PubMed ID: 8830979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers.
    Andreotti AC; Pianezzola E; Persiani S; Pacciarini MA; Strolin Benedetti M; Pontiroli AE
    J Clin Endocrinol Metab; 1995 Mar; 80(3):841-5. PubMed ID: 7883840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The disposition and urinary metabolism of 14C-labelled FCE 22891, a pro-drug of FCE 22101, in animals.
    Battaglia R; Benedetti MS; Frigerio E; Vicario G; Roncucci R
    J Antimicrob Chemother; 1990 Jan; 25(1):133-9. PubMed ID: 2318748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and metabolism of [3H]-pipethiaden in healthy volunteers.
    Plecitá Z; Spanĕl M; Ulc I; Rejŏlec V; Lapka R
    Eur J Drug Metab Pharmacokinet; 1992; 17(2):89-92. PubMed ID: 1425816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies.
    Sharma G; Mishra AK; Mishra P; Misra A
    AAPS PharmSciTech; 2009; 10(4):1321-30. PubMed ID: 19894122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of cabergoline.
    Del Dotto P; Bonuccelli U
    Clin Pharmacokinet; 2003; 42(7):633-45. PubMed ID: 12844325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
    Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
    Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of labetalol by animals and man.
    Martin LE; Hopkins R; Bland R
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects.
    Schmid J; Busch U; Heinzel G; Bozler G; Kaschke S; Kummer M
    Drug Metab Dispos; 1995 Nov; 23(11):1206-13. PubMed ID: 8591720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
    Rains CP; Bryson HM; Fitton A
    Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of spironolactone in man.
    Abshagen U; Rennekamp H; Luszpinski G
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Dec; 296(1):37-45. PubMed ID: 1012347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of the novel serotonin agonist, LY228729, in monkeys and rats.
    Swanson SP; Catlow J
    Drug Metab Dispos; 1992; 20(1):102-7. PubMed ID: 1346983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
    Prakash C; Kamel A; Anderson W; Howard H
    Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.